Filing Details
- Accession Number:
- 0001104659-19-050627
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-09-18 21:37:41
- Reporting Period:
- 2019-09-16
- Accepted Time:
- 2019-09-18 21:37:41
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1709401 | Rubius Therapeutics Inc. | RUBY | Biological Products, (No Disgnostic Substances) (2836) | 042688109 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1746845 | L. Christopher Carpenter | C/O Rubius Therapeutics, Inc. 399 Binney Street, Suite 300 Cambridge MA 02139 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-09-16 | 36,123 | $2.87 | 70,966 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-09-16 | 36,123 | $10.13 | 34,843 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2019-09-17 | 11,877 | $2.87 | 46,720 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-09-17 | 11,877 | $10.05 | 34,843 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-09-16 | 36,123 | $0.00 | 36,123 | $2.87 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-09-17 | 11,877 | $0.00 | 11,877 | $2.87 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 583,034 | 2027-10-24 | No | 4 | M | Direct | |
| 571,157 | 2027-10-24 | No | 4 | M | Direct |
Footnotes
- The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.31, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.21, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- 25% of this option shall vest on September 18, 2018, then in 12 equal quarterly installments thereafter.
Billionaire Hedge Funds
